Loading…
Based on limited metadata, this FDA Warning Letter issued on April 1, 2020, targets Homeomart Indibuy, a company involved in drug manufacturing or distribution. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. Further review of the complete warning letter would be necessary to identify the specific compliance issues cited.